International Society for Pediatric and Adolescent Diabetes (ISPAD) 2025
Category: Congress
Join leading experts at this 90-minute BR1DGE symposium to explore how early screening and timely intervention could transform outcomes and redefine the future of T1D care.
Register now
Stephen Gitelman
Stephen Gitelman is Professor of Pediatrics and Director of the Pediatric Diabetes Program at the University of California at San Francisco (UCSF). He received his undergraduate training at Princeton University, medical school training at the University of North Carolina, and completed his Pediatric residency and endocrine fellowship training at UCSF, where he has been ever since.
He holds the Mary B. Olney MD /KAK Distinguished Professorship in Pediatric Diabetes and Clinical Research. He is a clinical trialist attempting to find safe and effective means to preserve beta cell function in type 1 diabetes. He is a Clinical Center Director for the NIH sponsored consortia TrialNet; an investigator in the Immune Tolerance Network; and works closely with industry partners.
Loredana Marcovecchio
Loredana Marcovecchio is a Clinical Scientist and Consultant in Paediatric Endocrinology and Diabetes at the Department of Paediatrics, University of Cambridge, and Cambridge University Hospitals NHS Foundation Trust. Her clinical and research interests focus on childhood-onset type 1 diabetes (T1D). Since 2005, she has been actively involved in the design and conduct of both observational and interventional clinical studies aimed at improving the early detection and prevention of vascular complications in children and adolescents with T1D.
More recently, her work has expanded to encompass the prevention and treatment of type 1 diabetes, with a leading role in coordinating immunotherapy trials in children and adolescents recently diagnosed with T1D, as well as observational studies involving individuals in the early stages of the disease. Her research has resulted in numerous peer-reviewed publications and has contributed to national and international clinical guidelines on T1D management. Since 2020, she has served as a member of the Guidelines Editorial Committee of the International Society for Paediatric and Adolescent Diabetes (ISPAD). She is currently vice-President of the INNODIA.
Holly O’Donnell
Dr. O’Donnell is a Licensed Clinical Psychologist and an Assistant Professor of Pediatrics at the University of Colorado’s Barbara Davis Center for Diabetes. Her research interests include:
1) psychological impact of screening for type 1 diabetes (genetic risk and autoantibodies);
2) psychological aspects of living with type 1 diabetes (e.g., fear of hypoglycemia, diabetes distress, burnout);
3) screening for psychological barriers to adherence and integration into clinical care.
She is a member of the Psychosocial Committees for TEDDY and TrialNet, and serves as the consulting psychologist for Autoimmune Screening in Kids (ASK) Study at the Barbara Davis Center. Clinically, she enjoys working with patients of all ages and their families to address psychological aspects of living with type 1 diabetes and improve quality of life. Dr. O’Donnell trained as a pediatric psychologist and completed a two-year postdoctoral fellowship in pediatric type 1 diabetes prior to becoming faculty.
Jacques Beltrand
Jacques Beltrand is Professor of Pediatrics and Developmental Biology at Hôpital Necker Enfants Malades, Paris. He is also the co-leader of a research team focused on immunology and genetics in diabetes and endocrine diseases at the renowned Institut Cochin, Paris. His work aims to advance pediatric care and endocrine research, with a particular focus on diabetes, metabolism, and nutritional influences on disease progression.
He has received numerous accolades throughout his career, including the “Clinical Research Prize” from the Young Pediatrician Association in 2004, and the prestigious “Research Prize” from the Delessert Institute for his work on insulin secretion in children.
Redrawing the T1D Map: How Early Detection Is Transforming Care for Children
AGENDA
14:00–14:05 – Welcome and Introduction (Stephen Gitelman)
14:05–14:25 – Screening Is Driving the Transformation in T1D (Loredana Marcovecchio)
14:25–14:45 –Talking Transformation with Young People and Their Families (Holly O’Donnell)
14:45–15:05 –The Clinical Significance of Beta-cell Preservation in Early-stage T1D (Jacques Beltrand)
15:05–15:25 – Charting the Course: New Horizons in T1D Management (Stephen Gitelman)
15:25–15:30 – Close (Stephen Gitelman)
MEETING OBJECTIVES
- Discover the benefits of early detection of T1D in young people and how insights from T1D screening initiatives can inform the development of screening programs around the world
- Explore how to navigate discussions with people making the decision to undergo screening
- Discuss the importance of beta-cell preservation and its relevance in the current and emerging therapeutic landscape